The Nobel Laureate's CRISPR Company Just Pulled the Plug

Three big problems have haunted the allogeneic field for years. First, graft-versus-host disease (GVHD): the donor cells can attack the patient's own tissues, essentially turning the treatment into a friendly fire incident. Second, host-versus-graft rejection: the patient's immune system recognizes the donor cells as invaders and wipes them out before they can do their job. Third, and perhaps most damning, limited persistence: even when the cells survive long enough to start fighting cancer, they often don't stick around for a lasting response.

It's like hiring a bouncer who gets kicked out of the club before last call.

Caribou tried to solve these issues with its CRISPR platform, advancing two programs into clinical trials: vispa-cel for B-cell non-Hodgkin lymphoma and CB-011 for multiple myeloma. CB-011 even earned the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, a fast-track label that signals the agency sees real promise. But promise and proof are different currencies in biotech.

Follow the Money (While It Lasts)

Caribou didn't run out of cash overnight. As of June 30, the company reported $183.9 million in cash and marketable securities. That was down from $142.8 million at the end of 2025, but it wasn't fumes. The company still had runway, potentially into the second half of 2027 by some estimates.

The problem wasn't the bank balance; it was what it would cost to fill it back up. Its accumulated deficit since founding had ballooned to $596.5 million. And the stock had already dropped more than 50% over the prior twelve months, making any future fundraise brutally dilutive.

The company's board approved the restructuring on October 2, and Caribou explicitly pointed to the difficult financing environment for allogeneic CAR-T as the driver. Translation: investors stopped believing the science could beat the biology fast enough to justify more checks. The expected restructuring costs alone will run $15 million to $19 million, with most layoffs wrapping up by year's end.

A Sector-Wide Reckoning

Caribou isn't just one company failing. It's a signal flare for the entire allogeneic CAR-T field.

The fundamental value proposition (cheaper, faster, available off the shelf) hasn't changed. Neither has the fundamental problem: no allogeneic CAR-T product has yet achieved widespread regulatory approval. Meanwhile, autologous CAR-T keeps racking up approvals and building physician confidence.

The market dynamic is straightforward. Payers and oncologists will not trade away durable cancer responses just because the manufacturing is more convenient. If allogeneic cells can't match autologous durability, the cost savings don't matter. You wouldn't buy a cheaper parachute if it only worked half the time.

Some companies are still pushing forward, exploring next-generation edits, stealth engineering, and alternative cell types like CAR-NK (natural killer cells instead of T cells). But the financing window is narrowing, and Caribou's collapse will make every remaining allogeneic player's next fundraise harder.

What Comes Next

Caribou says it's exploring a merger, acquisition, business combination, or asset sale. No timeline has been set, and the company will only update shareholders if its board approves a specific deal.

What's left to buy? A sophisticated CRISPR editing platform, intellectual property from a lab that literally helped invent the technology, and whatever clinical data has been generated from two early-stage programs. For the right acquirer (a pharma company with deep pockets and patience, perhaps), those assets could still hold value.

But the equity story that began with a Nobel laureate and the promise of democratized cancer treatment? That chapter is closed. Caribou's journey from Berkeley startup incubator to billion-dollar promise to dollar-stock wind-down is a reminder of something biotech investors learn over and over again: brilliant science is necessary, but it's never sufficient. The biology has to cooperate. The money has to last. And the market has to believe.

This time, all three said no.

The $3.95 Million Drug That Costs More Than Most Houses

Ultragenyx just priced its new gene therapy Fayuvi at $3.95 million per patient, making it the second most expensive drug in the world. It's a one-time treatment for a fatal childhood brain disease with zero alternatives, and it's reigniting the fiercest debate in biotech: who pays for a genetic cure?